文献速递泌尿生殖腹部MR

采用酰胺质子转移加权MRI评估膀胱癌新辅助免疫化疗反应

Evaluating Neoadjuvant Immunochemotherapeutic Response for Bladder Carcinoma Using Amide Proton Transfer-Weighted MRI.
PubMed 文献 · Acad Radiol · 2025-01-09

前瞻性研究纳入2021年6月至2023年7月病理确诊膀胱癌患者,于新辅助免疫化疗前后行APTw和扩散加权MRI,从APTw及ADC图提取直方图特征,按术后膀胱切除标本病理分为pCR与非pCR组,评估各参数预测肿瘤反应的诊断效能。

要点

  • 治疗前APTw均值评估肿瘤反应的AUC最高,为0.85(原文写作AUC:0.75-0.93)。
  • pCR组治疗后APTw值明显下降、ADC值明显升高(P<0.05均)。
  • 非pCR组各参数变化无显著差异(P>0.05均)。

核心结论

  • APTw与扩散加权MRI衍生的MRI参数均可作为评估免疫化疗疗效的有价值无创影像生物标志物,并可能用于指导个体化精准治疗。

研究设计与样本

  • 前瞻性研究,纳入2021年6月至2023年7月病理确诊的膀胱癌参与者,于新辅助免疫化疗前后行包含APTw和扩散加权MRI的检查,以治疗后膀胱切除标本组织学评估为参考标准分为pCR组(无残留肿瘤)与非pCR组。

关键影像表现/征象

  • 治疗前APTw与扩散加权MRI衍生的多个影像生物标志物在组间存在显著差异(P<0.05均)。
  • pCR组治疗后APTw值明显下降、ADC值明显升高(P<0.05均)。
  • 非pCR组参数变化无显著差异(P>0.05均)。

诊断标准与关键数值

  • 基线APTw均值评估肿瘤反应的诊断效能最高,AUC为0.85(原文写作AUC:0.75-0.93)。
  • 以治疗后膀胱切除标本组织学评估为参考标准,pCR定义为无残留肿瘤。

临床应用与阅片要点

  • 治疗前APTw均值可能作为评估膀胱癌新辅助免疫化疗反应的影像生物标志物。
  • 治疗后APTw值下降、ADC值升高可能提示pCR。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: To investigate the feasibility of amide proton transfer-weighted (APTw) and diffusion-weighted MRI in evaluating the response of bladder cancer (BCa) to neoadjuvant immunochemotherapy.

MATERIALS AND METHODS: From June 2021 to July 2023, participants with pathologically confirmed BCa were prospectively recruited to undergo MRI examinations, including APTw and diffusion-weighted MRI before and after neoadjuvant immunochemotherapy. Histogram analysis features (mean, median, and entropy) were extracted from pre- and post-treatment APTw and apparent diffusion coefficient (ADC) maps, respectively. Participants were categorized into pCR (pathological complete response, no residual tumor) and non-pCR groups based on histologic evaluation of post-treatment cystectomy specimens. The diagnostic efficacy of parameters in predicting tumor responsiveness was evaluated by calculating the area under receiver operating characteristic curve (AUC).

RESULTS: Significant differences were found in several imaging biomarkers derived from pre-treatment APTw and diffusion-weighted MRI (P<0.05 for all). The baseline APTw mean values yielded the highest diagnostic performance, with an AUC of 0.85 (AUC: 0.75-0.93), for evaluating tumor responsiveness. For the pCR group, APTw values markedly decreased while ADC values noticeably increased at post-treatment MRI (P<0.05 for all). However, the parameter changes in non-pCR group were not significant (P>0.05 for all).

CONCLUSION: MRI parametrics derived from APTw and diffusion-weighted MRI can both serve as valuable noninvasive imaging biomarkers for evaluating the efficacy of immunochemotherapy and may be used to guide personalized precision therapy.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Kong L, Weng B, Cai Q, et al. Evaluating Neoadjuvant Immunochemotherapeutic Response for Bladder Carcinoma Using Amide Proton Transfer-Weighted MRI. Acad Radiol. 2025. PMID: 39794161. doi:10.1016/j.acra.2024.11.060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。